<DOC>
	<DOCNO>NCT00003693</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness dolastatin 10 treat patient refractory relapse acute leukemia , chronic myelogenous leukemia blast phase , myelodysplastic syndrome .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Refractory Relapsed Acute Leukemia , Myelodysplastic Syndrome , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity dolastatin 10 patient chronic myelogenous leukemia blast phase , refractory relapse acute leukemia , myelodysplastic syndrome . II . Assess possible antileukemia effect treatment patient . OUTLINE : This dose escalation study . Patients receive dolastatin 10 intravenous ( IV ) bolus every 3 week . Patients receive 2-12 course therapy absence disease progression unacceptable toxicity . In absence dose limit toxicity ( DLT ) first cohort 3 patient , subsequent cohort 3 patient receive escalate dos dolastatin 10 . If DLT occur 2 3 patient give dose level , dose escalation cease next low dose declare maximum tolerated dose . Patients follow death . PROJECTED ACCRUAL : This study accrue 25 patient within 8 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose chronic myelogenous leukemia blastic phase , refractory relapse acute leukemia , myelodysplastic syndrome ( refractory anemia excess blast ( RAEB ) , RAEB transformation , chronic myelomonocytic leukemia ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL SGPT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy recover ( unless evidence rapid disease progression ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>